Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Alimera Sciences Inc's Business Segments
Alimera Sciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2024
Reportable Segments
2
Largest Segment
United States Segment
Total Revenue
$ 26
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2024
- United States Segment67.1%
- International Segment36.1%
Revenue by Reportable Segment - Q2 FY2024
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| United States Segment | $ 18 | 67.1% |
| International Segment | $ 9 | 36.1% |
Description of Alimera Sciences Inc
Alimera Sciences Inc is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company primarily focuses on developing therapies for the treatment of retinal diseases, such as diabetic macular edema (DME) and age-related macular degeneration (AMD).
Alimera Sciences was founded in 2003 and is based in Alpharetta, Georgia, USA. The company's flagship product is Iluvien, which is a sustained-release intravitreal implant indicated for the treatment of DME. Iluvien delivers a microdose of the corticosteroid fluocinolone acetonide directly into the eye to reduce inflammation and edema, thus improving visual acuity and reducing the need for frequent injections.
The development and regulatory approval process of Iluvien has been a significant milestone for Alimera Sciences. The company conducted several clinical trials to establish the safety and efficacy of the product, ultimately leading to its approval by the U.S. Food and Drug Administration (FDA) in 2014. Iluvien has also received regulatory approvals in several other countries, including those in Europe, Canada, and the Middle East.
In addition to Iluvien, Alimera Sciences has a pipeline of other potential therapies targeting retinal diseases. The company is actively engaged in research and development activities to explore innovative treatment options and improve patient outcomes. They collaborate with leading academic institutions, research organizations, and clinicians to advance their scientific understanding of ocular diseases and therapeutic interventions.
As a pharmaceutical company, Alimera Sciences is committed to promoting the accessibility and affordability of its products. The company works closely with healthcare providers, insurers, and patient assistance programs to ensure that patients can access and receive the necessary treatment for their retinal conditions.
Furthermore, Alimera Sciences also distinguishes itself through its strong focus on education and support services for both healthcare professionals and patients. They provide training and resources to ophthalmologists and retina specialists to enhance their knowledge and proficiency in the use of Iluvien and other potential therapies. Additionally, the company offers patient support programs to help individuals navigate their treatment journey and manage their ocular health.
Overall, Alimera Sciences Inc is dedicated to advancing the field of ophthalmology and improving the lives of patients with retinal diseases. Through its innovative products, research endeavors, and educational initiatives, the company strives to make a meaningful impact on the eye care industry and contribute to the optimization of patient care.
Alimera Sciences was founded in 2003 and is based in Alpharetta, Georgia, USA. The company's flagship product is Iluvien, which is a sustained-release intravitreal implant indicated for the treatment of DME. Iluvien delivers a microdose of the corticosteroid fluocinolone acetonide directly into the eye to reduce inflammation and edema, thus improving visual acuity and reducing the need for frequent injections.
The development and regulatory approval process of Iluvien has been a significant milestone for Alimera Sciences. The company conducted several clinical trials to establish the safety and efficacy of the product, ultimately leading to its approval by the U.S. Food and Drug Administration (FDA) in 2014. Iluvien has also received regulatory approvals in several other countries, including those in Europe, Canada, and the Middle East.
In addition to Iluvien, Alimera Sciences has a pipeline of other potential therapies targeting retinal diseases. The company is actively engaged in research and development activities to explore innovative treatment options and improve patient outcomes. They collaborate with leading academic institutions, research organizations, and clinicians to advance their scientific understanding of ocular diseases and therapeutic interventions.
As a pharmaceutical company, Alimera Sciences is committed to promoting the accessibility and affordability of its products. The company works closely with healthcare providers, insurers, and patient assistance programs to ensure that patients can access and receive the necessary treatment for their retinal conditions.
Furthermore, Alimera Sciences also distinguishes itself through its strong focus on education and support services for both healthcare professionals and patients. They provide training and resources to ophthalmologists and retina specialists to enhance their knowledge and proficiency in the use of Iluvien and other potential therapies. Additionally, the company offers patient support programs to help individuals navigate their treatment journey and manage their ocular health.
Overall, Alimera Sciences Inc is dedicated to advancing the field of ophthalmology and improving the lives of patients with retinal diseases. Through its innovative products, research endeavors, and educational initiatives, the company strives to make a meaningful impact on the eye care industry and contribute to the optimization of patient care.
Alimera Sciences Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for the treatment of retinal diseases. The company focuses primarily on conditions that lead to vision impairment, particularly those affecting the back of the eye, such as diabetic macular edema (DME) and other retinal diseases.
Segments
1. Therapeutic Segment: Alimera’s primary focus lies in the therapeutic treatment of retinal diseases. This segment is crucial as it addresses the significant unmet medical needs of patients suffering from various ocular conditions.
2. Commercial Operations: This segment involves the marketing and distribution of their approved products. Alimera has established partnerships and collaborations to enhance its market reach and ensure that its products are accessible to healthcare providers and patients.
3. Research and Development: Alimera invests in R&D to explore new ophthalmic therapies and improve existing ones. This segment focuses on conducting clinical trials and studies to validate the safety and efficacy of new treatments.
Products
1. ILUVIEN:
- ILUVIEN is Alimera Sciences’ flagship product, which is designed for the treatment of diabetic macular edema (DME).
- It is a sustained-release intravitreal implant that delivers the drug fluocinolone acetonide over a prolonged period (up to 36 months).
- The product is aimed particularly at patients who are inadequately managed with available therapies and is administered in a surgical setting.
- ILUVIEN has shown significant results in reducing the risk of vision loss in patients with DME, thereby improving their quality of life.
2. Dexamethasone Implant (Ozurdex):
- While not directly an Alimera product, the company may engage in collaborations involving dexamethasone implants, which are also used to treat edema associated with retinal diseases.
- This segment could include partnerships or agreements to provide combination therapies that enhance treatment outcomes.
3. Pipeline Products:
- Alimera is involved in the development of additional investigational products aimed at treating retinal diseases. The company’s pipeline may include products targeting DME, retinal vein occlusion, and other ocular conditions related to inflammation and edema.
- The company is committed to advancing new formulations and drug delivery systems that could improve patient adherence and outcomes.
Services
1. Patient Support Programs: Alimera offers comprehensive patient support services to help individuals navigate their treatment journey. These programs often include educational resources, assistance with drug administration, and access to support networks for patients diagnosed with retinal diseases.
2. Healthcare Provider Education: Alimera invests in ongoing education for healthcare professionals to ensure they are informed about the latest advancements in retinal disease treatment. This may involve seminars, webinars, and distribution of educational materials related to the management of DME and other eye diseases.
3. Clinical Trial Management: The company often collaborates with clinical research organizations to conduct trials aimed at demonstrating the safety and efficacy of new therapies. Their services in this area include protocol development, patient recruitment, data management, and regulatory compliance.
4. Collaborative Research Initiatives: Alimera engages in partnerships with academic and research institutions to foster innovation in ophthalmic research. These collaborations aim to develop cutting-edge therapies and contribute to the scientific community’s understanding of retinal diseases.
Summary
Alimera Sciences Inc. operates in a specialized market focused on advancing the treatment of retinal diseases, particularly through its innovative product, ILUVIEN. The company is committed to enhancing patient outcomes through research, education, and support services, working closely with healthcare professionals to address the complexities of managing retinal diseases. The ongoing development of new therapies and enhancements to existing treatments underscore Alimera’s dedication to improving vision and quality of life for patients suffering from these conditions.
Segments
1. Therapeutic Segment: Alimera’s primary focus lies in the therapeutic treatment of retinal diseases. This segment is crucial as it addresses the significant unmet medical needs of patients suffering from various ocular conditions.
2. Commercial Operations: This segment involves the marketing and distribution of their approved products. Alimera has established partnerships and collaborations to enhance its market reach and ensure that its products are accessible to healthcare providers and patients.
3. Research and Development: Alimera invests in R&D to explore new ophthalmic therapies and improve existing ones. This segment focuses on conducting clinical trials and studies to validate the safety and efficacy of new treatments.
Products
1. ILUVIEN:
- ILUVIEN is Alimera Sciences’ flagship product, which is designed for the treatment of diabetic macular edema (DME).
- It is a sustained-release intravitreal implant that delivers the drug fluocinolone acetonide over a prolonged period (up to 36 months).
- The product is aimed particularly at patients who are inadequately managed with available therapies and is administered in a surgical setting.
- ILUVIEN has shown significant results in reducing the risk of vision loss in patients with DME, thereby improving their quality of life.
2. Dexamethasone Implant (Ozurdex):
- While not directly an Alimera product, the company may engage in collaborations involving dexamethasone implants, which are also used to treat edema associated with retinal diseases.
- This segment could include partnerships or agreements to provide combination therapies that enhance treatment outcomes.
3. Pipeline Products:
- Alimera is involved in the development of additional investigational products aimed at treating retinal diseases. The company’s pipeline may include products targeting DME, retinal vein occlusion, and other ocular conditions related to inflammation and edema.
- The company is committed to advancing new formulations and drug delivery systems that could improve patient adherence and outcomes.
Services
1. Patient Support Programs: Alimera offers comprehensive patient support services to help individuals navigate their treatment journey. These programs often include educational resources, assistance with drug administration, and access to support networks for patients diagnosed with retinal diseases.
2. Healthcare Provider Education: Alimera invests in ongoing education for healthcare professionals to ensure they are informed about the latest advancements in retinal disease treatment. This may involve seminars, webinars, and distribution of educational materials related to the management of DME and other eye diseases.
3. Clinical Trial Management: The company often collaborates with clinical research organizations to conduct trials aimed at demonstrating the safety and efficacy of new therapies. Their services in this area include protocol development, patient recruitment, data management, and regulatory compliance.
4. Collaborative Research Initiatives: Alimera engages in partnerships with academic and research institutions to foster innovation in ophthalmic research. These collaborations aim to develop cutting-edge therapies and contribute to the scientific community’s understanding of retinal diseases.
Summary
Alimera Sciences Inc. operates in a specialized market focused on advancing the treatment of retinal diseases, particularly through its innovative product, ILUVIEN. The company is committed to enhancing patient outcomes through research, education, and support services, working closely with healthcare professionals to address the complexities of managing retinal diseases. The ongoing development of new therapies and enhancements to existing treatments underscore Alimera’s dedication to improving vision and quality of life for patients suffering from these conditions.